Purple Biotech Announces Q3 2025 Financial Results and Advances CAPTN-3 Platform

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.Purple Biotech ( (PPBT) ) just unveiled an update. On November 14, 2025, Purple Biotech announced its third-quarter financial results and business update. The company highlighted the development of its CAPTN-3 platform, including the initiation of a second tri-specific antibody targeting TROP2 and achieving a manufacturing milestone for IM1240. With a cash position of $10.5 million as of September 30, 2025, Purple Biotech anticipates a cash runway into the first half of 2027, supporting significant milestones. The company plans to conduct toxicology studies and initiate a Phase 1 study for IM1240 in 2026. Financially, Purple Biotech reported a decrease in research and development expenses and operating loss compared to the previous year, primarily due to reduced costs associated with the CM24 Phase 2 study. The most recent analyst rating on (PPBT) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page. Spark’s Take on PPBT Stock According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform. Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score. To see Spark’s full report on PPBT stock, click here. More about Purple Biotech Purple Biotech Ltd. is a clinical-stage company based in Rehovot, Israel, focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies designed to engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. Average Trading Volume: 7,846,812 Technical Sentiment Signal: Sell Current Market Cap: $7.5M